Our lead asset, LTG-001, a novel serotonergic formulation designed to redefine the standard of care for acute relief of chronic pain. By leveraging our patented delivery platform, we are moving beyond traditional treatments toward a more effective, science-driven solution.

Currently in the preclinical stage, we are charging ahead with a clear milestone in sight: Phase 1 clinical trials by 2027. Stay tuned as we bridge the gap between breakthrough science and patient relief.